Domainex looks to partner and progress TBK1/IKKepsilon program to the clinic
This article was originally published in Scrip
Executive Summary
The Cambridge, UK-based drug discovery company Domainex has reported that small molecule compounds from its IKKepsilon program have demonstrated activity against the IL-17 signalling pathway, potentially paving the way for new treatments for autoimmune diseases.